Revolution Medicines (RVMD) — pipeline, SEC filings & news

Pipeline — registered trials by phase

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

— · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC · Recruiting · est. 2028-06

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

— · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma · Active Not Recruiting · est. 2026-06

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

— · NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC · Recruiting · est. 2029-10

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

— · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma · Recruiting · est. 2029-05-10

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

— · NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC · Recruiting · est. 2027-12-01

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

— · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC · Recruiting · est. 2029-03

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

— · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC · Recruiting · est. 2028-12-30

Source: ClinicalTrials.gov (trials where Revolution Medicines is lead sponsor; 18 active or completed) and Drugs@FDA (1 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.

SEC filings — insider trading forms excluded

8-K2026-09-01Current report (material event)
8-K2026-08-26Current report (material event)
SCHEDULE 13G2026-08-14SCHEDULE 13G
SCHEDULE 13G/A2026-08-13SCHEDULE 13G/A
SCHEDULE 13G2026-08-13SCHEDULE 13G
10-Q2026-08-05Quarterly report
8-K2026-08-05Current report (material event)
SCHEDULE 13G2026-07-29SCHEDULE 13G
8-K2026-06-22Current report (material event)
SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
10-Q2026-05-06Quarterly report
8-K2026-05-06Current report (material event)
DEFA14A2026-04-28DEFA14A
ARS2026-04-28Annual report to holders
DEF 14A2026-04-27Proxy statement
8-K2026-04-17Current report (material event)
8-K2026-04-16Current report (material event)
424B52026-04-15Prospectus (offering)
424B52026-04-15Prospectus (offering)
305B22026-04-15305B2
FWP2026-04-15FWP
424B52026-04-13Prospectus (offering)
424B52026-04-13Prospectus (offering)
8-K2026-04-13Current report (material event)
SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
424B52026-02-25Prospectus (offering)
S-82026-02-25Employee stock plan
10-K2026-02-25Annual report
8-K2026-02-25Current report (material event)
SCHEDULE 13G/A2026-02-17SCHEDULE 13G/A
SCHEDULE 13G/A2026-02-10SCHEDULE 13G/A
SCHEDULE 13G/A2026-02-09SCHEDULE 13G/A
SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
10-Q2025-11-05Quarterly report
8-K2025-11-05Current report (material event)
SCHEDULE 13G2025-11-05SCHEDULE 13G
8-K2025-10-17Current report (material event)
8-K2025-09-10Current report (material event)
SCHEDULE 13G2025-08-14SCHEDULE 13G
SCHEDULE 13G/A2025-08-14SCHEDULE 13G/A

Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.

Revolution Medicines RVMD

Pipeline — registered trials by phase

SEC filings — insider trading forms excluded